Dr Belinda Kiely

Senior Research Fellow
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +61 2 9562 5043
Fax +61 2 9565 1863

Map

Selected grants

2013

  • Advance care planning in incurable cancer patients with disease progression on first line chemotherapy: a randomised trial.; Tattersall M, Silvester W, Clayton J, Detering K, Hall J, Butow P, Kiely B, Cebon J, Clarke S, Bell M; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Evaluation of a web-based tool for estimating and explaining prognosis in advanced cancer; Kiely B, Stockler M, Butow P, Tattersall M, Simes R; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2011

  • Using scenarios to estimate and explain survival time to people with incurable cancer; Kiely B, Stockler M; American Society of Clinical Oncology (USA)/Young Investigator Award.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Kiely, B., Phillips, K. (2009). Managing cancer in pregnancy. In Monica Robotin, Ian Olver and Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physicians Handbook, (pp. 231-265). London: Imperial College Press.

Journals

  • West, T., Kiely, B., Stockler, M. (2014). Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. European Journal of Cancer, 50(11), 1916-1924. [More Information]
  • Garcia-Closas, M., Couch, F., Lindstrom, S., Michailidou, K., Schmidt, M., Brook, M., Orr, N., Rhie, S., Riboli, E., Feigelson, H., Carpenter, J., Balleine, R., et al (2013). Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics, 45(4), 392-398. [More Information]
  • Thientosapol, E., Tran, T., Della-Fiorentina, S., Adams, D., Chantrill, L., Stockler, M., Kiely, B. (2013). Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials. Internal Medicine Journal, 43(8), 883-888. [More Information]
  • Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Stockler, M., et al (2013). The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 31(28), 3565-3571. [More Information]
  • Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]
  • Kiely, B., Alam, M., Blinman, P., Tattersall, M., Stockler, M. (2012). Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials. Lung Cancer, 77(3), 537-544. [More Information]
  • Lord, S., Marinovich, M., Patterson, J., Wilcken, N., Kiely, B., Gebski, V., Crossing, S., Roder, D., Gattellari, M., Houssami, N. (2012). Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Medical Journal of Australia, 196(11), 688-692. [More Information]
  • Kiely, B., Stockler, M. (2012). Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer. Annals of Internal Medicine, 156(6), JC3-4-JC3-4. [More Information]
  • Kiely, B., Friedlander, M., Milne, R., Stanhope, L., Russell, P., Jenkins, M., Weideman, P., McLachlan, S., Grant, P., kConFab Investigators., et al (2011). Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. Familial Cancer, 10(3), 505-514. [More Information]
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2011). How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. Journal of Clinical Oncology, 29(4), 456-463. [More Information]
  • Kiely, B., Wilcken, N., Stockler, M. (2011). Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology, 29(9), 1092-1093. [More Information]
  • Kiely, B., Hossack, L., Shadbolt, C., Davis, A., Cassumbhoy, R., Moodie, K., Antill, Y., Mitchell, G. (2011). Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer. ANZ Journal of Surgery, 81(10), 688-693. [More Information]
  • Kiely, B., Stockler, M., Tattersall, M. (2011). Thinking and talking about life expectancy in incurable cancer. Seminars in Oncology, 38(3), 380-385. [More Information]
  • Kiely, B., Tattersall, M., Stockler, M. (2010). Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario. Journal of Clinical Oncology, 28(16), 2802-2804. [More Information]
  • Kiely, B., Jenkins, M., McKinley, J., Friedlander, M., Weideman, P., Milne, R., McLachlan, S., Hopper, J., Phillips, K. (2010). Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Research and Treatment, 120(3), 715-723. [More Information]

Conferences

  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
  • Kiely, B. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): a systematic review of recent randomized trials. Medical Oncology Group of Australia Annual Scientific Meeting, Sydney, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials. 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Kiely, B. (2010). Prospective study of adequacy of risk-reducing salpingo-oophorectomy in Australasian BRCA1/2 carriers and women at high familial risk of ovarian cancer in the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). The Australian New Zealand Gynaecological Oncology Group (ANZGOG) Annual Scientific Meeting 2010.
  • Kiely, B., Jenkins, M., McKinley, J., Friedlander, M., Weideman, P., Milne, R., McLachlan, S., Hopper, J., Phillips, K. (2009). Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). 2009 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Kiely, B., Phillips, K., Burnham, L., Russell, P., Jenkins, M., Weideman, P., Hopper, J., McLachlan, S., Friedlander, M. (2009). Prospective Study of Adequacy of Risk-Reducing Salpingo-Oophorectomy in Australasian BRCA1/2 Carriers in Women at High Familial Risk of Ovarian Cancer in the Kathleen Cunningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab). Clinical Oncological Society of Australia (COSA) 36th Annual Scientific Meeting, Gold Coast, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
  • Kiely, B. (2008). Practicalities of developing a breast magnetic resonance imaging (MRI) screening service for high risk women. 2008 Leura VI International Breast Cancer Conference. Westmead Breast Cancer Institute.
  • Kiely, B., Della-Fiorentina, S. (2007). Carboplatin and gemcitabine for advanced non-small cell lung cancer can a comorbidity score predict outcomes? 2007 Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting. Wiley-Blackwell Publishing Asia Pty Ltd.
  • Kiely, B., Goldrick, A., Levy, M., Sayaloune, P. (2007). Prevalence of hepatitis B in patients undergoing chemotherapy in South West Sydney. Proceedings of the 2007 Clinical Oncology Society of Australia (COSA) 34th Annual Scientific Meeting. Wiley-Blackwell Publishing Asia Pty Ltd.

Other

  • Kiely, B. (2011), Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer (HERA trial): Commentary by Dr Belinda Kiely.

2014

  • West, T., Kiely, B., Stockler, M. (2014). Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. European Journal of Cancer, 50(11), 1916-1924. [More Information]

2013

  • Garcia-Closas, M., Couch, F., Lindstrom, S., Michailidou, K., Schmidt, M., Brook, M., Orr, N., Rhie, S., Riboli, E., Feigelson, H., Carpenter, J., Balleine, R., et al (2013). Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics, 45(4), 392-398. [More Information]
  • Thientosapol, E., Tran, T., Della-Fiorentina, S., Adams, D., Chantrill, L., Stockler, M., Kiely, B. (2013). Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials. Internal Medicine Journal, 43(8), 883-888. [More Information]
  • Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Stockler, M., et al (2013). The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 31(28), 3565-3571. [More Information]
  • Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]

2012

  • Kiely, B., Alam, M., Blinman, P., Tattersall, M., Stockler, M. (2012). Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials. Lung Cancer, 77(3), 537-544. [More Information]
  • Lord, S., Marinovich, M., Patterson, J., Wilcken, N., Kiely, B., Gebski, V., Crossing, S., Roder, D., Gattellari, M., Houssami, N. (2012). Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Medical Journal of Australia, 196(11), 688-692. [More Information]
  • Kiely, B., Stockler, M. (2012). Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer. Annals of Internal Medicine, 156(6), JC3-4-JC3-4. [More Information]

2011

  • Kiely, B., Friedlander, M., Milne, R., Stanhope, L., Russell, P., Jenkins, M., Weideman, P., McLachlan, S., Grant, P., kConFab Investigators., et al (2011). Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. Familial Cancer, 10(3), 505-514. [More Information]
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2011). How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. Journal of Clinical Oncology, 29(4), 456-463. [More Information]
  • Kiely, B., Wilcken, N., Stockler, M. (2011). Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology, 29(9), 1092-1093. [More Information]
  • Kiely, B., Hossack, L., Shadbolt, C., Davis, A., Cassumbhoy, R., Moodie, K., Antill, Y., Mitchell, G. (2011). Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer. ANZ Journal of Surgery, 81(10), 688-693. [More Information]
  • Kiely, B., Stockler, M., Tattersall, M. (2011). Thinking and talking about life expectancy in incurable cancer. Seminars in Oncology, 38(3), 380-385. [More Information]
  • Kiely, B. (2011), Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer (HERA trial): Commentary by Dr Belinda Kiely.

2010

  • Kiely, B., Tattersall, M., Stockler, M. (2010). Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario. Journal of Clinical Oncology, 28(16), 2802-2804. [More Information]
  • Kiely, B., Jenkins, M., McKinley, J., Friedlander, M., Weideman, P., Milne, R., McLachlan, S., Hopper, J., Phillips, K. (2010). Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Research and Treatment, 120(3), 715-723. [More Information]
  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
  • Kiely, B. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): a systematic review of recent randomized trials. Medical Oncology Group of Australia Annual Scientific Meeting, Sydney, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials. 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Kiely, B. (2010). Prospective study of adequacy of risk-reducing salpingo-oophorectomy in Australasian BRCA1/2 carriers and women at high familial risk of ovarian cancer in the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). The Australian New Zealand Gynaecological Oncology Group (ANZGOG) Annual Scientific Meeting 2010.

2009

  • Kiely, B., Jenkins, M., McKinley, J., Friedlander, M., Weideman, P., Milne, R., McLachlan, S., Hopper, J., Phillips, K. (2009). Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). 2009 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Kiely, B., Phillips, K. (2009). Managing cancer in pregnancy. In Monica Robotin, Ian Olver and Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physicians Handbook, (pp. 231-265). London: Imperial College Press.
  • Kiely, B., Phillips, K., Burnham, L., Russell, P., Jenkins, M., Weideman, P., Hopper, J., McLachlan, S., Friedlander, M. (2009). Prospective Study of Adequacy of Risk-Reducing Salpingo-Oophorectomy in Australasian BRCA1/2 Carriers in Women at High Familial Risk of Ovarian Cancer in the Kathleen Cunningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab). Clinical Oncological Society of Australia (COSA) 36th Annual Scientific Meeting, Gold Coast, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.

2008

  • Kiely, B. (2008). Practicalities of developing a breast magnetic resonance imaging (MRI) screening service for high risk women. 2008 Leura VI International Breast Cancer Conference. Westmead Breast Cancer Institute.

2007

  • Kiely, B., Della-Fiorentina, S. (2007). Carboplatin and gemcitabine for advanced non-small cell lung cancer can a comorbidity score predict outcomes? 2007 Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting. Wiley-Blackwell Publishing Asia Pty Ltd.
  • Kiely, B., Goldrick, A., Levy, M., Sayaloune, P. (2007). Prevalence of hepatitis B in patients undergoing chemotherapy in South West Sydney. Proceedings of the 2007 Clinical Oncology Society of Australia (COSA) 34th Annual Scientific Meeting. Wiley-Blackwell Publishing Asia Pty Ltd.

To update your profile click here. For support on your academic profile contact .